Institution: | 1. School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, Queensland, Australia;2. Research and Development, Australian Red Cross Lifeblood, Brisbane, Queensland, Australia;3. School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, Queensland, Australia
Australian Infectious Diseases Research Centre, Global Virus Network Centre of Excellence, Brisbane, Queensland, Australia;4. Macopharma International GmbH, Langen, Germany;5. Macopharma, Tourcoing, France;6. Bavarian Red Cross Blood Service, Nuremberg, Germany;7. German Red Cross Blood Service NSTOB, Springe, Germany |
Abstract: | Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is unlikely to be a major transfusion-transmitted pathogen; however, convalescent plasma is a treatment option used in some regions. The risk of transfusion-transmitted infections can be minimized by implementing Pathogen Inactivation (PI), such as THERAFLEX MB-plasma and THERAFLEX UV-Platelets systems. Here we examined the capability of these PI systems to inactivate SARS-CoV-2. Study Design and Methods SARS-CoV-2 spiked plasma units were treated using the THERAFLEX MB-Plasma system in the presence of methylene blue (~0.8 μmol/L; visible light doses: 20, 40, 60, and 120 standard] J/cm2). SARS-CoV-2 spiked platelet concentrates (PCs) were treated using the THERAFLEX UV-platelets system (UVC doses: 0.05, 0.10, 0.15, and 0.20 standard] J/cm2). Samples were taken prior to the first and after each illumination dose, and viral infectivity was assessed using an immunoplaque assay. Results Treatment of spiked plasma with the THERAFLEX MB-Plasma system resulted in an average ≥5.03 log10 reduction in SARS-CoV-2 infectivity at one third (40 J/cm2) of the standard visible light dose. For the platelet concentrates (PCs), treatment with the THERAFLEX UV-Platelets system resulted in an average ≥5.18 log10 reduction in SARS-CoV-2 infectivity at the standard UVC dose (0.2 J/cm2). Conclusions SARS-CoV-2 infectivity was reduced in plasma and platelets following treatment with the THERAFLEX MB-Plasma and THERAFLEX UV-Platelets systems, to the limit of detection, respectively. These PI technologies could therefore be an effective option to reduce the risk of transfusion-transmitted emerging pathogens. |